vs
Side-by-side financial comparison of OneSpan Inc. (OSPN) and VIEMED HEALTHCARE, INC. (VMD). Click either name above to swap in a different company.
VIEMED HEALTHCARE, INC. is the larger business by last-quarter revenue ($76.2M vs $65.9M, roughly 1.2× OneSpan Inc.). OneSpan Inc. runs the higher net margin — 17.5% vs 7.4%, a 10.1% gap on every dollar of revenue. On growth, VIEMED HEALTHCARE, INC. posted the faster year-over-year revenue change (25.5% vs 4.1%). Over the past eight quarters, VIEMED HEALTHCARE, INC.'s revenue compounded faster (22.7% CAGR vs 4.0%).
OneSpan Inc. is an information security company based in Boston, Massachusetts. Services include an internet fraud prevention platform, multi-factor authentication tools and electronic signature software.
Viemed Healthcare, Inc. is a medical technology firm specializing in respiratory care solutions. It develops, manufactures and distributes portable ventilators, respiratory therapy devices and related support services, catering to acute care, post-acute care and home care segments across North America, Europe and key Asia-Pacific markets for patients with respiratory conditions.
OSPN vs VMD — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | ||
|---|---|---|
| Revenue | $65.9M | $76.2M |
| Net Profit | $11.6M | $5.6M |
| Gross Margin | 73.6% | 57.9% |
| Operating Margin | 22.5% | 11.0% |
| Net Margin | 17.5% | 7.4% |
| Revenue YoY | 4.1% | 25.5% |
| Net Profit YoY | — | 30.7% |
| EPS (diluted) | $0.39 | $0.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $65.9M | — | ||
| Q4 25 | $62.9M | $76.2M | ||
| Q3 25 | $57.1M | $71.9M | ||
| Q2 25 | $59.8M | $63.1M | ||
| Q1 25 | $63.4M | $59.1M | ||
| Q4 24 | $61.2M | $60.7M | ||
| Q3 24 | $56.2M | $58.0M | ||
| Q2 24 | $60.9M | $55.0M |
| Q1 26 | $11.6M | — | ||
| Q4 25 | $43.5M | $5.6M | ||
| Q3 25 | $6.5M | $3.5M | ||
| Q2 25 | $8.3M | $3.2M | ||
| Q1 25 | $14.5M | $2.6M | ||
| Q4 24 | $28.8M | $4.3M | ||
| Q3 24 | $8.3M | $3.9M | ||
| Q2 24 | $6.6M | $1.5M |
| Q1 26 | 73.6% | — | ||
| Q4 25 | 73.6% | 57.9% | ||
| Q3 25 | 73.6% | 57.5% | ||
| Q2 25 | 73.5% | 58.3% | ||
| Q1 25 | 74.3% | 56.3% | ||
| Q4 24 | 74.0% | 59.5% | ||
| Q3 24 | 73.9% | 59.3% | ||
| Q2 24 | 66.2% | 59.8% |
| Q1 26 | 22.5% | — | ||
| Q4 25 | 19.9% | 11.0% | ||
| Q3 25 | 14.4% | 7.8% | ||
| Q2 25 | 17.6% | 8.1% | ||
| Q1 25 | 27.1% | 6.5% | ||
| Q4 24 | 19.3% | 10.6% | ||
| Q3 24 | 20.0% | 9.7% | ||
| Q2 24 | 12.5% | 6.6% |
| Q1 26 | 17.5% | — | ||
| Q4 25 | 69.2% | 7.4% | ||
| Q3 25 | 11.4% | 4.9% | ||
| Q2 25 | 13.9% | 5.0% | ||
| Q1 25 | 22.9% | 4.4% | ||
| Q4 24 | 47.1% | 7.1% | ||
| Q3 24 | 14.7% | 6.7% | ||
| Q2 24 | 10.8% | 2.7% |
| Q1 26 | $0.39 | — | ||
| Q4 25 | $1.13 | $0.14 | ||
| Q3 25 | $0.17 | $0.09 | ||
| Q2 25 | $0.21 | $0.08 | ||
| Q1 25 | $0.37 | $0.06 | ||
| Q4 24 | $0.73 | $0.10 | ||
| Q3 24 | $0.21 | $0.10 | ||
| Q2 24 | $0.17 | $0.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | ||
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.8M | $13.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $272.0M | $141.5M |
| Total Assets | $383.1M | $199.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $49.8M | — | ||
| Q4 25 | $70.5M | $13.5M | ||
| Q3 25 | $85.6M | $11.1M | ||
| Q2 25 | $92.9M | $20.0M | ||
| Q1 25 | $105.2M | $10.2M | ||
| Q4 24 | $83.2M | $17.5M | ||
| Q3 24 | $77.5M | $11.3M | ||
| Q2 24 | $63.8M | $8.8M |
| Q1 26 | $272.0M | — | ||
| Q4 25 | $271.8M | $141.5M | ||
| Q3 25 | $238.3M | $133.6M | ||
| Q2 25 | $242.5M | $139.7M | ||
| Q1 25 | $231.1M | $134.8M | ||
| Q4 24 | $212.5M | $131.4M | ||
| Q3 24 | $194.6M | $125.0M | ||
| Q2 24 | $178.6M | $119.4M |
| Q1 26 | $383.1M | — | ||
| Q4 25 | $397.7M | $199.2M | ||
| Q3 25 | $343.5M | $202.4M | ||
| Q2 25 | $357.1M | $184.6M | ||
| Q1 25 | $333.8M | $178.1M | ||
| Q4 24 | $338.7M | $177.1M | ||
| Q3 24 | $289.3M | $169.5M | ||
| Q2 24 | $286.9M | $163.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | ||
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $18.4M |
| Free Cash FlowOCF − Capex | — | $9.7M |
| FCF MarginFCF / Revenue | — | 12.7% |
| Capex IntensityCapex / Revenue | — | 11.5% |
| Cash ConversionOCF / Net Profit | 2.44× | 3.27× |
| TTM Free Cash FlowTrailing 4 quarters | — | $11.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $28.2M | — | ||
| Q4 25 | $12.6M | $18.4M | ||
| Q3 25 | $11.3M | $18.4M | ||
| Q2 25 | $6.2M | $12.3M | ||
| Q1 25 | $29.4M | $2.9M | ||
| Q4 24 | $12.4M | $15.0M | ||
| Q3 24 | $14.0M | $12.7M | ||
| Q2 24 | $2.3M | $10.2M |
| Q1 26 | — | — | ||
| Q4 25 | $9.6M | $9.7M | ||
| Q3 25 | $8.8M | $10.7M | ||
| Q2 25 | $4.4M | $4.1M | ||
| Q1 25 | $27.7M | $-12.6M | ||
| Q4 24 | $10.5M | $3.2M | ||
| Q3 24 | $12.0M | $1.7M | ||
| Q2 24 | $26.0K | $1.2M |
| Q1 26 | — | — | ||
| Q4 25 | 15.3% | 12.7% | ||
| Q3 25 | 15.4% | 14.9% | ||
| Q2 25 | 7.3% | 6.5% | ||
| Q1 25 | 43.8% | -21.4% | ||
| Q4 24 | 17.1% | 5.2% | ||
| Q3 24 | 21.4% | 3.0% | ||
| Q2 24 | 0.0% | 2.3% |
| Q1 26 | — | — | ||
| Q4 25 | 4.7% | 11.5% | ||
| Q3 25 | 4.4% | 10.6% | ||
| Q2 25 | 3.1% | 12.9% | ||
| Q1 25 | 2.6% | 26.2% | ||
| Q4 24 | 3.2% | 19.5% | ||
| Q3 24 | 3.5% | 19.0% | ||
| Q2 24 | 3.7% | 16.3% |
| Q1 26 | 2.44× | — | ||
| Q4 25 | 0.29× | 3.27× | ||
| Q3 25 | 1.74× | 5.23× | ||
| Q2 25 | 0.75× | 3.88× | ||
| Q1 25 | 2.02× | 1.09× | ||
| Q4 24 | 0.43× | 3.47× | ||
| Q3 24 | 1.69× | 3.29× | ||
| Q2 24 | 0.35× | 6.94× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
OSPN
| Product and license | $35.5M | 54% |
| Services and other | $30.4M | 46% |
VMD
Segment breakdown not available.